Business context and reporting period
Repligen Corporation (Nasdaq: RGEN) filed this unaudited Form 10-Q for the quarter and nine months ended September 30, 2023. The company develops and sells technologies used in biopharmaceutical manufacturing and reports one operating and reportable segment.
Financial performance and liquidity
Amounts are in U.S. dollars; financial statement figures below are in millions except per-share data.
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Revenue | $141.2 | $200.7 | $483.0 | $614.8 |
| Gross margin | 25.9% | 56.9% | 45.0% | 58.5% |
| Income from operations | $4.8 | $52.7 | $55.5 | $175.8 |
| Net income | $18.2 | $40.4 | $67.1 | $137.2 |
| Diluted EPS | $0.32 | $0.71 | $1.18 | $2.39 |
| Operating cash flow | Not separately presented | Not separately presented | $84.9 | $110.2 |
- Q3 non-GAAP adjusted net income was $13.2 million, or $0.23 per diluted share, versus $44.4 million, or $0.77, a year earlier. Adjusted EBITDA was $14.5 million versus $57.9 million. These are company-defined non-GAAP measures.
- Cash and cash equivalents were $630.8 million at September 30, 2023, up from $523.5 million at December 31, 2022. Working capital was $615.1 million, compared with $593.9 million at year-end 2022.
- Cash flow from investing activities was a net source of $46.6 million for the nine months, largely reflecting $102.3 million from maturity of Treasury bills; cash used for acquisitions and capital expenditures partly offset this. Capital expenditures were $25.1 million, plus $2.7 million of capitalized software costs.
- Convertible senior notes had a $287.4 million principal amount and $286.0 million net carrying value, classified as current liabilities because they mature in July 2024. Holders may convert under the note terms; only nominal principal had been requested for conversion to date.
Material changes versus prior comparable periods
- Q3 revenue fell 29.7%; nine-month revenue declined 21.4%. Management attributed the decrease mainly to lower COVID-19-related demand, as customers used existing inventories, particularly affecting filtration products. Chromatography and Process Analytics performed strongly in the nine-month period, and price increases partly offset declines.
- Gross margin contracted substantially. Management cited lower sales and production volumes, product mix shifts away from higher-margin COVID-related consumables, inflation and freight costs, added capacity and depreciation, and restructuring charges.
- Q3 operating income and earnings declined sharply. Results included $24.0 million of restructuring costs and a $34.3 million gain from reducing the fair value of contingent consideration. The gain materially affected reported operating income; adjusted measures exclude it and other specified items.
- Investment income rose to $6.7 million in Q3 and $18.1 million for nine months, from $2.2 million and $3.0 million, respectively, primarily due to higher interest rates and invested balances. Q3 included a $6.5 million income tax benefit, versus a $7.1 million provision in Q3 2022.
- Operating cash flow declined to $84.9 million from $110.2 million for the nine months. The current period included lower net income, partially offset by working-capital benefits, including inventory reduction; lower accounts payable and accrued expenses used cash.
Outlook, management commentary, risks and unusual items
- No full-year revenue, earnings or margin guidance is provided in the filing. Management expects COVID-19-related demand trends and macroeconomic pressures to continue affecting results through the remainder of 2023; it expects R&D spending to gradually increase and operating expenses to rise as the business expands.
- The July 2023 restructuring consolidates some U.S. manufacturing operations, discontinues selected product SKUs and addresses excess pandemic-period materials. The company recorded approximately $24.0 million in charges through September, expects about $26 million for full-year 2023, and anticipates substantially completing the plan by year-end. Approximately $21 million of expected charges are non-cash, primarily inventory write-offs and accelerated depreciation; remaining costs are mainly employee-related.
- FlexBiosys was acquired in April 2023 for consideration valued at approximately $41.0 million, including cash, shares and contingent consideration. Purchase accounting remained preliminary. On October 2, after quarter-end, the company acquired Metenova for approximately $173 million in cash and company equity; final purchase-price allocation was not yet available.
- Management said existing cash is adequate for at least 24 months from the filing date, absent acquisitions of additional products, candidates or intellectual property. Additional financing may be needed for acquisitions; the filing warns that financing may be unavailable on acceptable terms and equity or debt issuance could dilute shareholders or restrict operations.
- Key risks include continued demand weakness, customer purchasing patterns, integration and restructuring execution, inflation and supply-chain costs, foreign-exchange exposure (which the company does not currently hedge), dependence on third-party manufacturing and partnerships, and financial-sector liquidity disruptions. The company reported less than $0.1 million in SVB accounts at September 30 and said it had moved operating activity to other banks.
- The filing reports no known legal proceedings expected to have a material adverse effect. Management concluded disclosure controls were effective; phased implementation of a new ERP system continues through 2024, with related control changes.
Important facts for investors to verify
- Whether demand and revenue stabilize as COVID-era customer inventories and purchasing patterns normalize, and whether stronger chromatography and Process Analytics sales persist.
- How much of Q3’s reported results reflects recurring operations versus restructuring costs and contingent-consideration fair-value gains; review the company’s non-GAAP reconciliations alongside GAAP results.
- Whether restructuring costs remain near the approximately $26 million estimate, the extent of realized savings, and any operational disruption from facility consolidation or SKU discontinuations.
- Funding and integration implications of the Metenova acquisition, including its final purchase-price allocation and effect on cash, equity and future performance.
- The settlement and liquidity implications of the $287.4 million notes maturing in July 2024, and cash availability after acquisitions and planned investment.